^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ligufalimab (AK117)

    i
    Other names: AK117, AK 117, AK-117
    Company:
    Akesobio
    Drug class:
    CD47 inhibitor
    Related drugs:
    10d
    A Study of Ivonescimab in First-Line ES-SCLC (clinicaltrials.gov)
    P2, N=180, Recruiting, Akeso
    New P2 trial
    |
    carboplatin • etoposide IV • Kaitanni (cadonilimab) • Yidafan (ivonescimab) • ligufalimab (AK117)
    2ms
    AK112-206: A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2, N=254, Active, not recruiting, Akeso | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    5-fluorouracil • capecitabine • oxaliplatin • irinotecan • leucovorin calcium • Yidafan (ivonescimab) • ligufalimab (AK117)
    4ms
    Anti-CD47 drug interference in pre-transfusion testing can be overcome by antigen masking. (PubMed, Transfusion)
    These findings emphasize the need for awareness and adaptation in immunohematology practices as anti-CD47 drugs continue to advance in clinical development, and highlight the utility of antigen masking strategies to enhance the safe administration of blood products to treated patients.
    Journal
    |
    CD47 (CD47 Molecule) • SIRPA (Signal Regulatory Protein Alpha)
    |
    magrolimab (ONO-7913) • lemzoparlimab (ABBV-IMAB-TJC4) • ligufalimab (AK117) • letaplimab (IBI188) • ontorpacept (PF-07901800)
    7ms
    A Phase III Study of Ivonescimab + Chemo With/Without AK117 vs Chemo in Metastatic Pancreatic Cancer (clinicaltrials.gov)
    P3, N=999, Not yet recruiting, Akeso
    New P3 trial
    |
    gemcitabine • albumin-bound paclitaxel • Yidafan (ivonescimab) • ligufalimab (AK117)
    9ms
    AK117-203: A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer (clinicaltrials.gov)
    P2, N=120, Recruiting, Akeso | N=80 --> 120 | Trial completion date: Oct 2023 --> Dec 2026 | Trial primary completion date: Jan 2023 --> Jul 2025
    Enrollment change • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative
    |
    albumin-bound paclitaxel • Yidafan (ivonescimab) • ligufalimab (AK117)
    9ms
    AK117-202: A Study of AK112 in Advanced Malignant Tumors (clinicaltrials.gov)
    P1/2, N=250, Active, not recruiting, Akeso | Recruiting --> Active, not recruiting | Trial completion date: Jan 2025 --> Jun 2026 | Trial primary completion date: Aug 2024 --> May 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Yidafan (ivonescimab) • ligufalimab (AK117)
    9ms
    AK117-104: A Trial of AK117 (Anti-CD47 Antibody) in Patients With Acute Myeloid Leukemia (clinicaltrials.gov)
    P1/2, N=68, Active, not recruiting, Akeso | Recruiting --> Active, not recruiting | N=160 --> 68 | Trial completion date: Jul 2024 --> Dec 2025 | Trial primary completion date: Jul 2023 --> Sep 2025
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    azacitidine • ligufalimab (AK117)
    9ms
    AK117-103: A Trial of AK117 (Anti-CD47) in Patients With Myelodysplastic Syndrome (clinicaltrials.gov)
    P1/2, N=136, Active, not recruiting, Akeso | Recruiting --> Active, not recruiting | Trial completion date: May 2024 --> Dec 2025 | Trial primary completion date: May 2023 --> Sep 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    azacitidine • ligufalimab (AK117)
    9ms
    AK112-206: A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2, N=254, Recruiting, Akeso | N=104 --> 254 | Trial completion date: Dec 2026 --> Aug 2028 | Trial primary completion date: Dec 2024 --> May 2026
    Enrollment change • Trial completion date • Trial primary completion date
    |
    5-fluorouracil • capecitabine • oxaliplatin • irinotecan • leucovorin calcium • Yidafan (ivonescimab) • ligufalimab (AK117)
    10ms
    Ligufalimab and Cadonilimab in Advanced Liver Cancers (clinicaltrials.gov)
    P2, N=64, Recruiting, University of Texas Southwestern Medical Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Kaitanni (cadonilimab) • ligufalimab (AK117)
    10ms
    A Study of AK129 With or Without AK117 in PD(L)1-refractory Classic Hodgkin Lymphoma (clinicaltrials.gov)
    P1/2, N=280, Recruiting, Akeso | Not yet recruiting --> Recruiting | Initiation date: Oct 2024 --> Jan 2025
    Enrollment open • Trial initiation date
    |
    ligufalimab (AK117)
    11ms
    Ligufalimab and Cadonilimab in Advanced Liver Cancers (clinicaltrials.gov)
    P2, N=64, Not yet recruiting, University of Texas Southwestern Medical Center
    New P2 trial
    |
    Kaitanni (cadonilimab) • ligufalimab (AK117)